Stoke Therapeutics Q2 EPS $(0.69) Misses $(0.64) Estimate, Sales $(2.48M) Miss $3.44M Estimate
Portfolio Pulse from Benzinga Newsdesk
Stoke Therapeutics reported Q2 losses of $0.69 per share, missing the analyst consensus estimate of $0.64 by 7.81%. This is a 9.52% decrease over losses from the same period last year. The company also reported quarterly sales of $2.48 million, missing the analyst consensus estimate of $3.44 million by 172.12%. This is a 176.79% decrease over sales from the same period last year.
August 07, 2023 | 11:22 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Stoke Therapeutics reported lower than expected earnings and sales for Q2, which could negatively impact the stock price.
Stoke Therapeutics reported lower than expected earnings and sales for Q2. This miss on both earnings and sales estimates could lead to a decrease in the stock price as it indicates the company's performance was not as strong as expected.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100